BFM
INDV icon

Boothbay Fund Management’s Indivior Pharmaceuticals INDV Stock Holding History

Boothbay Fund Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-128,406
Closed -$1.91M – 2006
2025
Q2 		$1.91M Sell
128,406
-171,701
-57% -$2M 0.04% 515
2025
Q1 		$2.81M Sell
300,107
-158,767
-35% -$1.67M 0.07% 355
2024
Q4 		$5.88M Buy
458,874
+181,637
+66% +$1.87M 0.15% 201
2024
Q3 		$2.73M Sell
277,237
-634,813
-70% -$7.43M 0.06% 427
2024
Q2 		$14.3M Sell
912,050
-62,512
-6% -$1.13M 0.34% 38
2024
Q1 		$20.8M Sell
974,562
-76,520
-7% -$1.44M 0.4% 31
2023
Q4 		$15.9M Buy
1,051,082
+104,874
+11% +$1.86M 0.4% 25
2023
Q3 		$20.5M Hold
946,208
– – 0.49% 24
2023
Q2 		$21.9M Buy
+946,208
New +$21.7M 0.48% 22

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Boothbay Fund Management's INDV Position: Q3 2025 in Review

Boothbay Fund Management sold out of Indivior Pharmaceuticals (INDV) in Q3 2025, closing a stake of 128,406 shares — an estimated $1.91M sold.

Boothbay Fund Management first reported a position in INDV in Q2 2023 and held it in 9 quarters. The position peaked at $21.9M in Q2 2023. 198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • Boothbay Fund Management reported no remaining Indivior Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 128,406 Indivior Pharmaceuticals shares in Q3 2025, an estimated $1.91M.
  • Boothbay Fund Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • Boothbay Fund Management's Indivior Pharmaceuticals position peaked at $21.9M in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.